Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E23.81 EPS (ttm)4.45 Insider Own0.40% Shs Outstand1.51B Perf Week2.22%
Market Cap160.18B Forward P/E11.32 EPS next Y9.36 Insider Trans0.40% Shs Float1.49B Perf Month5.13%
Income7.46B PEG0.97 EPS next Q1.90 Inst Own92.80% Short Float5.07% Perf Quarter30.49%
Sales17.44B P/S9.19 EPS this Y10.40% Inst Trans-1.85% Short Ratio5.71 Perf Half Y47.02%
Book/sh10.50 P/B10.09 EPS next Y16.79% ROA28.60% Target Price110.74 Perf Year64.74%
Cash/sh5.82 P/C18.20 EPS next 5Y24.67% ROE57.70% 52W Range58.81 - 110.64 Perf YTD41.09%
Dividend- P/FCF23.31 EPS past 5Y11.90% ROI18.70% 52W High-4.23% Beta0.77
Dividend %- Quick Ratio2.20 Sales past 5Y16.00% Gross Margin81.20% 52W Low80.17% ATR3.11
Employees6100 Current Ratio2.50 Sales Q/Q136.10% Oper. Margin56.20% RSI (14)57.18 Volatility3.39% 2.97%
OptionableYes Debt/Eq0.59 EPS Q/Q378.30% Profit Margin42.80% Rel Volume1.68 Prev Close105.93
ShortableYes LT Debt/Eq0.49 EarningsOct 28 AMC Payout0.00% Avg Volume13.23M Price105.96
Recom1.70 SMA20-0.02% SMA508.38% SMA20027.93% Volume22,191,040 Change0.03%
22-Aug-14Reiterated RBC Capital Mkts Outperform $102 → $115
15-Aug-14Initiated FBR Capital Outperform $125
11-Aug-14Reiterated Argus Buy $90 → $110
28-Jul-14Reiterated Maxim Group Buy $112 → $127
24-Jul-14Reiterated RBC Capital Mkts Outperform $96 → $102
28-Apr-14Reiterated Maxim Group Buy $101 → $112
21-Feb-14Reiterated Barclays Overweight $90 → $95
10-Feb-14Reiterated Argus Buy $84 → $90
05-Feb-14Reiterated RBC Capital Mkts Outperform $90 → $96
05-Feb-14Reiterated Needham Buy $85 → $95
05-Feb-14Reiterated Maxim Group Buy $98 → $101
04-Feb-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
28-Jan-14Reiterated Deutsche Bank Buy $95 → $132
06-Jan-14Reiterated UBS Buy $80 → $102
02-Jan-14Reiterated Maxim Group Buy $89 → $98
20-Dec-13Reiterated RBC Capital Mkts Outperform $80 → $90
01-Nov-13Reiterated Argus Buy $70 → $84
30-Oct-13Reiterated RBC Capital Mkts Outperform $72 → $80
30-Oct-13Reiterated Barclays Overweight $68 → $74
26-Jul-13Reiterated Stifel Buy $65 → $75
19-Sep-14 07:36PM  IBD 50 Stocks Setting Up, Including These 5 Medicals at Investor's Business Daily
06:35PM  IBD 50 Stocks Setting Up, Including These 5 Medicals at Investor's Business Daily
04:15PM  Spectrum Pharmaceuticals Out-Licenses Products in China Zacks
03:50PM  Eli Lilly's Trulicity Approved by FDA for Type II Diabetes Zacks
01:13PM  Why Gilead Sciences Could Gain 30% at Barrons.com
12:17PM  Gilead's Zydelig Approved In EU; Imbruvica In Wings at Investor's Business Daily
08:14AM  VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session Zacks
06:22AM  European Commission Grants Marketing Authorization for Gileads Zydelig┬« (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma Business Wire
18-Sep-14 04:35PM  Sanofi & MyoKardia Ink Deal to Develop Cardiomyopathies Zacks
04:02PM  Gilead Down on Weak Simtuzumab Data and Sovaldi News Zacks
10:52AM  2 Columbia Growth Funds Notch Impressive Three-Month Performance Benzinga
10:14AM  Gilead Sciences: Failed Trial Always a 'Long Shot' at Barrons.com
08:35AM  Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% Zacks
07:06AM  Repros Therapeutics (RPRX) Crumbles: Stock Falls by 10.5% Zacks
17-Sep-14 10:22PM  CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill at Forbes
06:25PM  Gilead's Sovaldi Usage Fades As Hep-C Patients Await Rivals Investor's Business Daily
06:15PM  Merck Posts Positive Data on Osteoporosis Drug Odanacatib Zacks
05:40PM  UCB-Amgen Reveals Positive Data on Romosozumab for PMO Zacks
03:30PM  Regeneron Gets Breakthrough Therapy Status for Eylea Zacks
02:25PM  3 Huge Stocks on Traders' Radars: SHLD, PFE, GILD at TheStreet
12:52PM  Video: Gilead Stock Falls On These Drug Setbacks at Investor's Business Daily
12:52PM  Gilead Stock Is Falling On These Drug Setbacks at Investor's Business Daily
11:20AM  Gilead Sciences: What to Make of Its Latest Failure? at Barrons.com
06:58AM  [$$] Gilead Cancer Treatment Fails at The Wall Street Journal
06:00AM  Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer Business Wire
16-Sep-14 06:53PM  Gilead Sciences Investor's Business Daily
05:21PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
05:01PM  Stocks Rise Ahead Of Fed, Led By Biotech, Chip Names at Investor's Business Daily
04:20PM  AstraZeneca and Eli Lilly Collaborate for Alzheimer's Drug Zacks
03:45PM  Gilead (GILD) Slips on Generic Sovaldi Licensing Deals Zacks
01:57PM  Gilead Up As Analyst Lifts Sovaldi Q3 Estimate at Investor's Business Daily
12:17PM  [$$] Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries at The Wall Street Journal
11:41AM  [$$] Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries at The Wall Street Journal
10:39AM  Gilead Sciences: Another Analyst Lifts Sovaldi Forecast at Barrons.com
09:09AM  Stock Futures Mildly Lower; Netflix, Gilead Still Sliding at Investor's Business Daily
01:12AM  [$$] Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries at The Wall Street Journal
12:01AM  Hitachi, Gilead, Amazon, Facebook: Intellectual Property at Bloomberg
15-Sep-14 10:56PM  [$$] Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries at The Wall Street Journal
09:30PM  [$$] Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries at The Wall Street Journal
08:57PM  [$$] Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries at The Wall Street Journal
06:26PM  [$$] Gilead to Allow Cheaper Hepatitis C Drug at The Wall Street Journal
05:23PM  $1,000-a-pill hep C treatment to be cheaper abroad at USA TODAY
05:06PM  Biotech still place to be: Pro CNBC
04:54PM  $1,000-a-pill hep C treatment to be cheaper abroad at USA TODAY
02:34PM  $1,000-a-pill hep C treatment to be cheaper abroad at USA TODAY
02:15PM  Gilead shares drop as plan emerges to discount Sovaldi in poorer regions at MarketWatch
02:00PM  Genomic Health Reveals Positive Oncotype DX Test Results Zacks
01:44PM  Gilead Deal to Sell Sovaldi in Poor Countries Meets Criticism at The Wall Street Journal
01:38PM  [video] Gilead Expands Access of Hepatitis C Drug in Developing Countries at TheStreet
01:20PM  Gilead will license cheaper, generic version of Sovaldi at San Jose Mercury News
01:19PM  Gilead shares drop as plan emerges to discount Sovaldi in poorer regions at MarketWatch
12:11PM  Gilead in deal with India labs to produce Sovaldi at Financial Times
11:35AM  Video: Gilead OKs Generic Sovaldi To Expand Access at Investor's Business Daily
11:35AM  Gilead OKs Generic Sovaldi To Expand Global Access at Investor's Business Daily
11:26AM  US STOCKS-Wall St little changed but tech weighs on Nasdaq Reuters
11:25AM  Generic deal reached on $1,000-a-pill hep C drug at USA TODAY
10:07AM  [$$] Gilead to Allow Cheaper Hepatitis C Drug at The Wall Street Journal
10:05AM  Gilead to license generic version of Sovaldi AP
09:30AM  A Fabulous Pharma ETF ETF Trends
09:15AM  Gilead to license generic version of Sovaldi AP
09:04AM  Gilead signs hepatitis C pact to cut drug cost for poor Reuters
08:17AM  Gilead to license generic version of Sovaldi AP
07:59AM  Gilead signs pact with 7 firms for cheap copies of hepatitis C drug Reuters
07:40AM  Gilead to license generic version of Sovaldi AP
07:19AM  [$$] Gilead to Allow Cheaper Hepatitis C Drug at The Wall Street Journal
07:13AM  Gilead Licenses Sovaldi to Mylan, Others For Developing Markets at Bloomberg
06:30AM  Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries Business Wire
06:25AM  Maker of Hepatitis C Drug Strikes Deal on Generics for Poor Countries at New York Times
06:25AM  Gilead, Maker of Hepatitis C Drug, Strikes Deal on Generics for Poor Countries at New York Times
06:25AM  Maker of Hepatitis C Drug Strikes Deal on Generics for Poor Countries at New York Times
06:06AM  Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others Reuters
13-Sep-14 08:02AM  Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers at Investor's Business Daily
12-Sep-14 06:46PM  Gilead to raise price for new hepatitis C drug above $84,000 Reuters
06:02PM  Most active Nasdaq-traded stocks AP
02:49PM  Gilead Sciences: Sovaldi Sales Slip But Less Than Feared at Barrons.com
01:29PM  Gilead Sciences: Sovaldi Sales Slip But Less Than Feared at Barrons.com
09:43AM  Retrophin, Gilead, And Our Healthcare Values at Forbes
08:02AM  5 Top Stocks With Rising Earnings Estimates at Investor's Business Daily
07:40AM  #PreMarket Primer: Friday, September 12: US Allies Vague About Participation In Syrian Airstrikes Benzinga
07:00AM  Sector Equity CEFs Excelled in August Morningstar
11-Sep-14 05:41PM  Medivation Eyes Blockbuster As Cancer Drug Gets An OK at Investor's Business Daily
04:55PM  Novartis Presents Data on Multiple Sclerosis Drug Gilenya Zacks
04:17PM  Stocks Bounce As Nasdaq, S&P 500 Close With Small Gains at Investor's Business Daily
03:45PM  Is This the Right Time to Buy Gilead Sciences (GILD) Stock? Zacks
02:46PM  Stocks Show Modest Losses; Biotechs Pressured Again at Investor's Business Daily
10:02AM  Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs at TheStreet
09:20AM  Short Sellers Remain Vigilant Against Biotechs at 24/7 Wall St.
07:59AM  The Zacks Analyst Blog Highlights: AbbVie, Infinity Pharmaceuticals, Keryx Biopharmaceuticals, Gilead and Amgen Zacks
10-Sep-14 05:40PM  PDL BioPharma Sees Higher-than-Expected Revenues in Q3 Zacks
04:20PM  Spectrum Pharmaceuticals to Advance Neutropenia Drug Zacks
03:30PM  Emergent BioSolutions Wins $29M Anthrax Vaccine Deal Zacks
03:05PM  Gilead Sciences, Inc. Could Be Taking A Break Before Even More Upside Benzinga
02:00PM  Myriad Genetics Posts Encouraging myPath Melanoma Data Zacks
01:25PM  Stocks Turn Higher After Soft Start; U.S. Silica Jumps at Investor's Business Daily
11:54AM  Stocks Up At Midday; Alexion Leads Biotech Rebound at Investor's Business Daily
10:51AM  Gilead Sciences: Don't Bet on Early Approval, Wells Fargo Says at Barrons.com
10:17AM  Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval Zacks
08:27AM  Burlington Stores, Quiksilver, Hospira, Mylan and Gilead Sciences highlighted as Zacks Bull and Bear of the Day Zacks
08:02AM  Under Armour, Apple, Gilead Among Big-Cap Leaders at Investor's Business Daily
07:39AM  ERBA Diagnostics (ERB) in Focus: Stock Up 7% Zacks
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
Whitley Richard JamesDirectorJun 02Sale80.955,000404,75015,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Sale81.3533,0002,684,514128,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Option Exercise16.4090,0001,475,550209,302May 16 02:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Sale80.6590,0007,258,752119,302May 16 02:52 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000021,290May 13 02:27 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Option Exercise23.3340,000933,132170,694May 12 03:38 PM
MILLIGAN JOHN FPresident and COOMay 08Option Exercise8.01100,000800,5001,038,048May 09 06:58 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Sale80.0040,0003,200,000130,694May 12 03:38 PM
Washington Robin LEVP, CFOMay 06Option Exercise24.913,00074,71552,832May 08 07:13 PM
Washington Robin LEVP, CFOMay 06Sale79.913,000239,73049,832May 08 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise21.5811,000237,325143,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Option Exercise26.995,000134,95017,778May 05 05:36 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise8.01140,6251,125,7034,570,012May 05 05:52 PM
MARTIN JOHN CChairman and CEOMay 01Sale79.02140,62511,112,0344,429,387May 05 05:52 PM
Whitley Richard JamesDirectorMay 01Sale78.635,000393,15012,778May 05 05:36 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale79.0813,0001,028,024130,694May 05 05:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM
MARTIN JOHN CChairman and CEOApr 01Sale73.26140,62510,302,0284,429,387Apr 03 03:20 PM
Cogan John FrancisDirectorMar 14Option Exercise14.3414,000200,72553,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Option Exercise16.4090,0001,475,550209,302Mar 18 01:36 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Sale75.8990,0006,829,705119,302Mar 18 01:36 PM
Cogan John FrancisDirectorMar 14Sale76.4414,0001,070,10139,542Mar 18 12:56 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Option Exercise21.5816,728360,90745,290Mar 12 01:39 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Sale79.3216,7281,326,83328,562Mar 12 01:39 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Option Exercise21.5831,000668,825117,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Option Exercise8.01140,6251,125,7034,397,860Mar 05 02:51 PM
MARTIN JOHN CChairman and CEOMar 03Sale81.74140,62511,495,3264,257,235Mar 05 02:51 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Sale81.8433,0002,700,68784,484Mar 05 02:50 PM
Washington Robin LEVP, CFOFeb 28Option Exercise22.3030,600682,49080,432Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Option Exercise24.0099,0002,375,550114,842Mar 04 02:56 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Sale83.5599,0008,271,93515,842Mar 04 02:56 PM
Washington Robin LEVP, CFOFeb 28Sale83.6530,6002,559,63549,832Mar 04 09:09 PM
MOORE NICHOLAS GDirectorFeb 26Option Exercise26.6220,000532,30020,000Feb 28 12:50 PM
MOORE NICHOLAS GDirectorFeb 26Sale84.0520,0001,681,0700Feb 28 12:50 PM
Washington Robin LEVP, CFOFeb 21Option Exercise23.605,000118,00054,832Feb 25 03:41 PM
Washington Robin LEVP, CFOFeb 21Sale83.245,000416,21849,832Feb 25 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Option Exercise22.0219,068419,78219,068Feb 21 02:32 PM
Washington Robin LEVP, CFOFeb 19Sale83.3696880,69249,832Feb 21 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Sale83.1219,0681,584,9900Feb 21 02:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Option Exercise14.5090,0001,305,225158,124Feb 19 02:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Sale81.3690,0007,322,22268,124Feb 19 02:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Option Exercise21.5816,728360,90731,861Feb 12 04:44 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Sale79.1016,7281,323,19815,133Feb 12 04:44 PM